---
title: "Hong Kong Stock Midday Review | Hang Seng Index rose 0.53% in the morning session, the biopharmaceutical sector continues to be strong"
description: "The Hong Kong Hang Seng Index rose 0.53% in the morning session, reporting 23,807 points, with the biopharmaceutical sector performing strongly. Hengrui Pharma is about to list on the Hong Kong stock "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/241150324.md"
published_at: "2025-05-21T04:09:03.000Z"
---

# Hong Kong Stock Midday Review | Hang Seng Index rose 0.53% in the morning session, the biopharmaceutical sector continues to be strong

> The Hong Kong Hang Seng Index rose 0.53% in the morning session, reporting 23,807 points, with the biopharmaceutical sector performing strongly. Hengrui Pharma is about to list on the Hong Kong stock market, and pharmaceutical stocks generally rose, with LaiKai Pharma-B up 17% and CanSino Biologics-B up 15%. CATL's stock price hit a new high on the second day of its listing, rising over 11%. Other pharmaceutical stocks such as AKESO and 3SBIO also saw significant gains. The overall turnover of the Hong Kong stock market in the morning session was HKD 119.3 billion

According to Zhitong Finance APP, the Hang Seng Index rose 0.53%, up 125 points, closing at 23,807 points; the Hang Seng Tech Index rose 0.43%; the Hang Seng Biotech Index rose 2.82%. The Hong Kong stock market had a turnover of HKD 119.3 billion in the morning session.

Pharmaceutical stocks continued to strengthen in the morning, with a strong momentum for domestic innovative drugs going overseas, and Hengrui Pharma is about to list on the Hong Kong stock market. LaiKai Pharma-B (02105) rose 17%; CanSino Biologics-B (09966) rose 15%; Ascentage Pharma-B (06855) rose 9.38%; Zai Lab (06127) rose 6%; Junshi Biosciences (01877) rose 7.4%; 3SBIO (01530) rose another 9%.

CATL (03750) rose over 11% on its second day of listing, with its stock price hitting a new high, as the company fully exercised its over-allotment option.

AKESO (09926) rose over 7%, as 3SBIO's PD-1 dual antibody going overseas set a new record, with the company’s Ivosidenib outperforming Keytruda.

Xiansheng Pharmaceutical (02096) rose over 9%, as the FGFR2b-targeted ADC completed the first patient dosing in Phase I clinical trials, and the sales of Xianoxin have significantly increased recently.

Fuhong Hanlin (02696) rose over 7%, as HLX13 completed the first patient dosing in clinical research for advanced liver cancer.

MicroPort Medical (00853) rose over 6%, with Morgan Stanley stating that the sale of MicroPort Robotics shares has a minimal impact on the company's revenue and profit forecasts.

Laopu Gold (06181) rose over 6%, as the first hour of the 618 sales event broke the record with over 40 million in sales, and institutions expect its valuation level to improve.

Boyaa Interactive (00434) rose over 10%, as Bitcoin approached USD 107,000, with the company holding approximately 3,350 Bitcoins

### Related Stocks

- [600276.CN - Hengrui Pharma](https://longbridge.com/en/quote/600276.CN.md)
- [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md)
- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)
- [00434.HK - BOYAA](https://longbridge.com/en/quote/00434.HK.md)
- [03115.HK - ISHARESHSI](https://longbridge.com/en/quote/03115.HK.md)
- [06855.HK - ASCENTAGE-B](https://longbridge.com/en/quote/06855.HK.md)
- [01877.HK - JUNSHI BIO](https://longbridge.com/en/quote/01877.HK.md)
- [JPM.US - JPMorgan Chase](https://longbridge.com/en/quote/JPM.US.md)
- [00853.HK - MICROPORT](https://longbridge.com/en/quote/00853.HK.md)
- [06127.HK - JOINN](https://longbridge.com/en/quote/06127.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone Pharmaceuticals Says CS2009 Gets FDA IND Clearance For Phase II Trial | CStone Pharmaceuticals :CS2009 RECEIVES FDA IND CLEARANCE FOR PHASE II TRIAL | [Link](https://longbridge.com/en/news/276024762.md) |
| Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | [Link](https://longbridge.com/en/news/275893661.md) |
| Indian Pharma Co USV Signs Definitive Agreement To Acquire 79% Equity Stake In Nutritionalab - Statement | Hindustan Unilever Ltd :USV HAS SIGNED DEFINITIVE AGREEMENT TO ACQUIRE 79% EQUITY STAKE IN NUTRITIONALAB - STATEMENT | [Link](https://longbridge.com/en/news/275704159.md) |
| Akums Drugs And Pharmaceuticals Dec-Quarter Consol Net Profit 663.2 Million Rupees | Akums Drugs and Pharmaceuticals Ltd :AKUMS DRUGS AND PHARMACEUTICALS DEC-QUARTER CONSOL NET PROFIT 663.2 MILLION RUPEESA | [Link](https://longbridge.com/en/news/275892892.md) |
| ‘XRP is the North Star for Ripple’: Garlinghouse keeps door open for more M&A in second half of 2026 | Ripple CEO Brad Garlinghouse indicated that while significant acquisitions are unlikely in the near term, he remains ope | [Link](https://longbridge.com/en/news/275646537.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
